Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 06101 | Wellpoint Federal | MAC - Part A | IL |
| 06201 | Wellpoint Federal | MAC - Part A | MN |
| 06301 | Wellpoint Federal | MAC - Part A | WI |
| 06102 | Wellpoint Federal | MAC - Part B | IL |
| 06202 | Wellpoint Federal | MAC - Part B | MN |
| 06302 | Wellpoint Federal | MAC - Part B | WI |
| 13101 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13201 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13102 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13202 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13282 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13292 | Wellpoint Federal | A and B and HHH MAC | NY |
| 14411 | Wellpoint Federal | A and B and HHH MAC | RI |
| 14211 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14311 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14511 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14111 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14112 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14212 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14312 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14512 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14412 | Wellpoint Federal | A and B and HHH MAC | RI |
Billing and coding article A59101: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59101 (Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A59101: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (Billing and Coding, effective 2026-04-01)
- Covered ICD-10-CM codes
- 836
- 2 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 4
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| B10.89 | Other human herpesvirus infection |
| B20 | Human immunodeficiency virus [HIV] disease |
| C79.32 | Secondary malignant neoplasm of cerebral meninges |
| C79.40 | Secondary malignant neoplasm of unspecified part of nervous system |
| C79.49 | Secondary malignant neoplasm of other parts of nervous system |
| C81.00 | Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site |
| C81.01 | Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.02 | Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.03 | Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.04 | Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.05 | Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.06 | Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.07 | Nodular lymphocyte predominant Hodgkin lymphoma, spleen |
| C81.08 | Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.09 | Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites |
| C81.10 | Nodular sclerosis Hodgkin lymphoma, unspecified site |
| C81.11 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.12 | Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.13 | Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.14 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.15 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.16 | Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.17 | Nodular sclerosis Hodgkin lymphoma, spleen |
| C81.18 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites |
Procedure codes: J9312 (Injection, rituximab, 10 mg), Q5115 (Injection, rituximab-abbs, biosimilar, (truxima), 10 mg), Q5119 (Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg), Q5123 (Injection, rituximab-arrx, biosimilar, (riabni), 10 mg).
Coverage indications, limitations and medical necessity
Background
Rituximab is an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the CD20 antigen, a protein expressed most B cells surface results in B—cell depletion. Initially used for anti-neoplastic therapy, it has been licensed for use in several autoimmune disorders. Rituximab has been used off-label for a multitude of indications (1). Rituximab carries a black-box warning about the following risks associated with rituximab use: fatal infusion reactions, tumor lysis syndrome, severe skin and mouth reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy (2). Throughout the policy, rituximab refers to rituximab and biosimilar as appropriate.
The FDA initially approved rituximab on November 26, 1997. An alert was issued on September 25, 2013, by the FDA to highlight additional Boxed Warning information about Rituximab regarding patients with prior Hepatitis B virus (HBV) infection; HBV reactivation may occur when the body’s immune system is impaired. HBV cases and patient deaths continued to occur. In response, the FDA recommends screening and monitoring prior to and throughout rituximab’s duration in patients with prior HBV infection (3).
This policy addresses the off-labeled, non-compendia use of rituximab for non-anti-neoplastic conditions. The use of rituximab for labeled indications is covered and not addressed in this policy. Off-label use for anti-neoplastic therapy is not addressed in this policy.
Definitions:
First-line therapy - an agent used in the initial treatment of a condition.
Adverse event - a documented event that contraindicates further use of the medication or side effects that are not likely to be transient and resolve with further treatment or impair functional capacity and/or daily living activities.
Lack of efficacy - the lack of an expected or desired effect related to therapy when the dosage and duration of therapy meet published standards.
Refractory disease - when the patient fails to respond to all first-line therapies that are standard of care for the condition.
Relapse disease - a recurrence of the disease condition that does not respond to first-line treatments and/or standard of care therapies.
Indications of Coverage:
ANCA-associated vasculitis (AAV)
Rituximab is recommended for induction of remission in patients with severe or relapsing ANCA-associated vasculitis, particularly granulomatosis with polyangiitis and microscopic polyangiitis, as an alternative to cyclophosphamide. It is favored for maintenance therapy over azathioprine due to its superior efficacy in reducing relapse rates. Rituximab is recommended for patients unable to receive first-line therapies and as part of tailored treatment strategies based on individual risk factors. The safety profile of rituximab is comparable to cyclophosphamide, with fewer long-term concerns.
Antibody-mediated rejection (AMR)
Rituximab may be considered as second-line treatment or as part of a combination treatment for AMR in kidney, lung, and cardiac transplant patients.
Rituximab may be considered in highly sensitized patients as part of desensitization protocols awaiting donor transplants.
All other uses of rituximab for AMR prevention or treatment are considered investigational.
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Rituximab may be considered in patients who have failed intravenous immunoglobulin (IVIG), glucocorticoids, and plasma exchange.
Rituximab is considered investigational for CIDP as a first line therapy
Hemophilia (acquired)
Rituximab may be considered in patients with acquired or refractory hemophilia as first-line combination therapy of corticosteroids and Rituximab.
Rituximab may also be considered as a second-line agent and for use in refractory disease.
Idiopathic inflammatory myopathy
Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterized by muscle weakness and inflammation, but in anti-synthetase syndrome, arthritis and interstitial lung disease are more frequent and often inaugurate the disease.
Clinical practice guidelines recommend Rituximab as a treatment option for IIMs with extra muscular (lung) involvement from a large multi-disciplinary workgroup.(23) However, this is based on expert opinion, without supporting evidence.(24)
Immune-mediated myopathies
(Dermatomyositis (DM), Polymyositis (PM), Antisynthetase syndrome, Immune- mediated necrotizing myopathy (IMNM), Inclusion body myositis (IBM), Nonspecific myositis)
Rituximab may be considered in refractory cases of immune-mediated myopathies that have failed all first-line therapies.
For all other uses, rituximab is considered investigational for immune-mediated myopathies.
Immune thrombocytopenic purpura (ITP)
Rituximab will be covered when all of the following criteria are met:
• Documented lack of response of at least one first line therapy
• Documented risk for bleeding (at least one of the following)
• Severe ITP (bleeding symptoms)
• Risk factors for bleeding are present
• In preparation for procedures or surgery with risk of bleeding
• Professional or lifestyle risk for trauma
• Persistent or chronic disease (>6 months)
Immunoglobulin G4-related disease (IgG4-RD)
Rituximab may be considered a second-line therapy in refractory or relapsed cases of IgG4-RD that have failed all first-line therapies, or there is an absolute contraindication to glucocorticoid use.
For all other uses, rituximab is considered investigational for IgG4-RD.
Minimal change disease
Rituximab may be considered for children with steroid-dependent, steroid-sensitive nephrotic syndrome who have continuing frequent relapses despite optimal combinations of prednisone and corticosteroid-sparing agents or who have serious adverse effects of therapy.
Rituximab may be considered in adult patients with frequently relapsing or glucocorticoid-dependent minimal change disease who have also failed to attain a durable remission with cyclophosphamide or calcineurin inhibitors.
Rituximab in adults with glucocorticoid-resistant MCD is investigational.
Rituximab for first- or second-line therapy for minimal change disease is investigational.
Multiple sclerosis
Rituximab may be considered a second-line option in patients with refractory or remitting multiple sclerosis who failed first-line therapy.
Sjögren’s and systemic sclerosis
Rituximab may be considered when corticosteroids and other immunosuppressive agents were ineffective
Rituximab is considered investigational for Sjögren’s syndrome as a first line therapy
Susac Syndrome
Rituximab may be considered for use in Susac Syndrome in patients with severe or extremely severe disease presentations, particularly when initial treatments such as corticosteroids and intravenous immunoglobulin (IVIG) are inadequate. It is often incorporated into a multi-drug regimen alongside mycophenolate mofetil for more aggressive management. While the use of rituximab is based primarily on case reports and clinical observations, it plays a significant role in managing severe or resistant cases of Susac Syndrome due to the absence of standardized treatment protocols.
Thrombotic thrombocytopenic purpura (TTP)
Rituximab may be considered in patients with severe, refractory, or relapsed thrombotic thrombocytopenic purpura (acquired) who have failed first-line therapy (plasma exchange and glucocorticoids).
The use of rituximab for initial therapy and relapse prevention is investigational.
Limitations of Coverage:
Behcet’s syndrome
Rituximab is considered investigational for Behcet’s syndrome.
Cerebral ataxia
Rituximab is considered investigational for cerebral ataxia.
Polyarteritis nodosa
Rituximab is considered investigational for polyarteritis nodosa. Use in refractory cases may be considered on a case to case basis.
Summary of evidence (opening)
ANCA-Associated Vasculitis (AAV)
ANCA-associated vasculitis (AAV) is an autoimmune disorder characterized by inflammation of small to medium blood vessels often leading to damage in vital organs such as the kidneys and lungs. In recent years, rituximab—a monoclonal antibody that depletes B cells targeting the CD20 antigen—has gained prominence as a treatment option for AAV (88). According to guidelines from sources like the American College of Rheumatology/Vasculitis Foundation and the KDIGO 2024 Clinical Practice Guideline, rituximab is recommended for both induction and maintenance of remission in AAV due to its efficacy and safety profile (89,90).
The efficacy of rituximab has been validated through randomized controlled trials like RAVE and RITUXVAS, showing comparable or superior remission induction compared to cyclophosphamide, especially in patients with relapsing disease (91). The MAINRITSAN and RITAZAREM trials further support its superiority over azathioprine for maintenance therapy, exhibiting reduced relapse rates and effective long-term disease control (91,92).
Safety assessments indicate a favorable profile for rituximab, with lower risks of malignancies and fertility issues compared to traditional cyclophosphamide therapy and manageable adverse effects primarily involving infections and infusion reactions (91).
The contractor cites 99 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2022-11-01
- Current revision effective
- 2026-04-01
- MCD version
- 7
Other related documents: A60253 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L39297 cover?
Rituximab is an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the CD20 antigen, a protein expressed most B cells surface results in B—cell depletion. Initially used for anti-neoplastic therapy, it has been licensed for use in several autoimmune disorders. Rituximab has been used off-label for a multitude of indications (1). Rituximab carries a black-box warning about the following risks associated… The full 1,070-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L39297 apply to?
Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L39297?
The companion billing and coding article A59101 lists 836 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L39297?
A denial under LCD L39297 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59101's 836 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.